Inactivated trivalent influenza vaccine

ApprovedVaccine

Inactivated trivalent influenza vaccine is one of 44 biologic programs targeting Thrombocytopenic Purpura. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thrombocytopenic PurpuraActive, not recruiting

InfluenzaActive, not recruiting

Thrombocytopenic PurpuraPreclinical

Active, not recruiting

InfluenzaApproved

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Inactivated trivalent influenza vaccine

AAdvagene Biopharma Co. Ltd.

Approved

6 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Crestor

AstraZeneca

Preclinical

1 6

Avigan

AAppili Therapeutics Inc.

Preclinical

6 7

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 8

Fluvirin

Novartis

Preclinical

3 9

Afluria

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

MF-59

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza6 trials

A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult

Completed·AAdvagene Biopharma Co. Ltd.·Phase 2·NCT03784885·345 enrolled

Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Completed·—·Phase 4·NCT00934245·4,598 enrolled

Influenza Vaccine To Prevent Adverse Vascular Events:Pilot

Completed·MMcMaster University·Phase 4·NCT01945268·107 enrolled

Show 3 more trials

Influenza Immunization of Children in India

Completed·UUniversity of Colorado, Denver·Phase 4·NCT01680679·18,163 enrolled

Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)

Unknown status·MMcMaster University·Phase 4·NCT02762851·5,000 enrolled

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China··NCT04355806·160 enrolled

Thrombocytopenic Purpura1 trial

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Completed·—·N/A·NCT01713855·10 enrolled

Elderly Participants1 trial

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

Completed·SSeqirus·Phase 2·NCT00479648·612 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Inactivated trivalent influenza vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inactivated trivalent influenza vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inactivated trivalent influenza vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advagene Biopharma Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: AAdvagene Biopharma Co. Ltd.

Inactivated trivalent influenza vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza6 trials

Thrombocytopenic Purpura1 trial

Elderly Participants1 trial

References

Drug Info

Quick Facts

Related News